Nektar Therapeutics NKTR
NASDAQ NKTR
$74.19 -2.18 (-2.85%)
At close: Sep 4, 2026 · 4:00 PM EDT

Nektar Therapeutics (NKTR) Net Equity Issued and Repurchased (2010 - 2026)

Nektar Therapeutics (NKTR) posted quarterly Net Equity Issued and Repurchased of $93.1 million for Q1 2026, up 26.5% quarter-over-quarter from $73.6 million in Q4 2025.

Analysis

Nektar Therapeutics (NKTR) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends

Nektar Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $93.1 million for Q1 2026.

  • In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $93.1 million; the TTM figure through Mar 2026 stood at $201.0 million (changed N/A YoY), while the FY2025 annual figure was $108.1 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased for Q1 2026 stood at $93.1 million, up from $73.6 million in the prior quarter.
  • The five-year high for Net Equity Issued and Repurchased was $93.1 million in Q1 2026, with the low at $34.3 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 141.90 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Nektar Therapeutics 2.45 Bn 1.77 Bn 3.04 Mn 677.13 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 677.13 Mn
Mar 31, 2026 432.40 Mn
Sep 30, 2025 34.30 Mn
Mar 31, 2012 479,000.00
Dec 31, 2011 -4.29 Mn
Sep 30, 2011 523,000.00
Jun 30, 2011 1.59 Mn
Mar 31, 2011 221.96 Mn
Dec 31, 2010 1.75 Mn
Sep 30, 2010 994,000.00
Jun 30, 2010 1.37 Mn
Mar 31, 2010 4.78 Mn